Stockhead on MSN2d
AdAlta prioritises ‘East to West’ cellular immunotherapy strategy to drive value creationAdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.
FY25 saw AdAlta focus on increasing its corporate muscle, with two new board members and additional advisors engaged. ...
HotCopper.com on MSN2d
'East to West': AdAlta unveils new strategy to find drug candidates, but appears to've ditched AD-214AdAlta (ASX:1AD) has unveiled a new grand plan to take cell therapy candidates from Southeast Asia, firm them up in ...
The ASX 200 Health Care Index rose 3.20% in January but Morgans notes February faces volatility with Trump's tariffs playbook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback